FMA
TGTX icon

FNY Managed Accounts’s TG Therapeutics TGTX Stock Holding History

FNY Managed Accounts’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-252
Closed -$2K – 576
2017
Q1 		$2K Buy
+252
New +$1.81K 0.01% 711
2016
Q2 		– Sell
-4,258
Closed -$36.3K – 417
2016
Q1 		$36.3K Buy
+4,258
New +$37.3K 0.06% 158

Other funds holding TGTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BM
Bridger Management New York $128M AUM 9.54% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CCI
Columbus Circle Investors $2.28B AUM 135.57% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
SAM
Senzar Asset Management New York $34.7M AUM 0.56% 1-Year Est. Return

FNY Managed Accounts's TGTX Position: Q2 2017 in Review

FNY Managed Accounts sold out of TG Therapeutics (TGTX) in Q2 2017, closing a stake of 252 shares — an estimated $2K sold.

FNY Managed Accounts first reported a position in TGTX in Q1 2016 and held it in 2 quarters. The position peaked at $36.3K in Q1 2016. 106 funds tracked by Wall St. Rank hold TGTX as of Q2 2017.

  • FNY Managed Accounts reported no remaining TG Therapeutics position as of Q2 2017 after selling out during the quarter.
  • FNY Managed Accounts sold 252 TG Therapeutics shares in Q2 2017, an estimated $2K.
  • FNY Managed Accounts first reported a position in TG Therapeutics in Q1 2016 and held it in 2 quarters.
  • FNY Managed Accounts's TG Therapeutics position peaked at $36.3K in Q1 2016.
  • 106 funds tracked by Wall St. Rank held TG Therapeutics as of Q2 2017.

Based on FNY Managed Accounts's 13F filing for Q2 2017, filed 10 Aug 2017.